Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity (original) (raw)
- Experimental Oncology
- Published: 01 August 1998
British Journal of Cancer volume 78, pages 336–343 (1998)Cite this article
- 318 Accesses
- 48 Citations
- 6 Altmetric
- Metrics details
Abstract
DMXAA (5,6-dimethylxanthenone-4-acetic acid), a novel anti-tumour agent currently undergoing clinical evaluation, appears to mediate its anti-tumour effects through immune modulation and the production of the cytokine tumour necrosis factor-alpha (TNF). Our previous studies have shown that thalidomide, a potent inhibitor of TNF biosynthesis that has numerous biological effects, including inhibition of tumour angiogenesis, unexpectedly augments the anti-tumour response in mice to DMXAA. We show here that thalidomide (100 mg kg(-1)) has no effect when administered with inactive doses of DMXAA, and that it must be given simultaneously with an active dose of DMXAA to have its maximum potentiating effect on the growth of the murine Colon 38 adenocarcinoma. To address the issue of whether inhibition of serum TNF production is important for potentiation of anti-tumour activity, we have tested three potent analogues of thalidomide. All three analogues, when co-administered with DMXAA to mice at doses lower than those used with thalidomide, inhibited TNF production and were effective in potentiating the anti-tumour activity of DMXAA against transplanted Colon 38 tumours. One of the analogues, N-phenethyltetrafluorophthalimide, was 1000-fold more potent than thalidomide and at a dose of 0.1 mg kg(-1) in combination with DMXAA (30 mg kg(-1)) cured 100% of mice, compared with 67% for the group treated with DMXAA alone. We also tested pentoxifylline and found it to suppress TNF production in response to DMXAA and to potentiate the anti-tumour effect of DMXAA. The results are compatible with the hypothesis that pharmacological reduction of serum TNF levels might benefit the anti-tumour effects of DMXAA and suggest new strategies for therapy using this agent.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
Author information
Authors and Affiliations
- Auckland Cancer Society Research Centre, University of Auckland School of Medicine, New Zealand
LM Ching
Authors
- LM Ching
You can also search for this author inPubMed Google Scholar - WL Browne
You can also search for this author inPubMed Google Scholar - R Tchernegovski
You can also search for this author inPubMed Google Scholar - T Gregory
You can also search for this author inPubMed Google Scholar - BC Baguley
You can also search for this author inPubMed Google Scholar - BD Palmer
You can also search for this author inPubMed Google Scholar
Rights and permissions
About this article
Cite this article
Ching, L., Browne, W., Tchernegovski, R. et al. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.Br J Cancer 78, 336–343 (1998). https://doi.org/10.1038/bjc.1998.495
- Issue Date: 01 August 1998
- DOI: https://doi.org/10.1038/bjc.1998.495